27810-64-6

Usage

Uses

Used in Pharmaceutical Industry:
Isoquinoline-5-carboxylic acid is used as an intermediate in the synthesis of pharmaceuticals and organic compounds for its ability to serve as a building block in the creation of various types of drugs.
Used in Medicinal and Chemical Research:
Isoquinoline-5-carboxylic acid is used as a subject of study for its potential anti-inflammatory and antitumor properties, making it an area of interest for researchers in the fields of medicine and chemistry.

InChI:InChI=1/C10H7NO2/c12-10(13)9-3-1-2-7-6-11-5-4-8(7)9/h1-6H,(H,12,13)

Upstream product

• 16675-59-5 methyl isoquinoline-5-carboxylate 
• 19981-17-0 sodium cyanamide 
• 34784-04-8 5-bromoisoquinoline 
• 3132-99-8 m-bromobenzoic aldehyde 
• 63927-20-8 (3-bromo-benzylidenamino)-acetaldehyde diethylacetal 
• 27655-41-0 isoquinoline-5-carbonitrile 

Downstream Products

• 16675-59-5 methyl isoquinoline-5-carboxylate 
• 1092768-78-9 C₂₆H₂₇ClN₂O₃ 
• 406192-81-2 isoquinoline hydrazide 
• 215788-34-4 5-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline 
• 607-32-9 5-nitroisoquinoline 
• 1253955-69-9 tert-butyl 2-(isoquinoline-5-carboxamido)-1-phenylethylcarbamate 
• 1198319-72-0 (R)-(8-oxo-2-(2-phenethyl)-2,4,5,6,7,8-hexahydropyrazolo[4,3-e][1,4]diazepin-6-yl)methyl isoquinoline-5-carboxylate 
• 1036739-94-2 C₂₆H₂₉N₃O₃ 
• 1029491-99-3 C₁₈H₈Cl₃N₅S 
• 569-51-7 benzene-1,2,3-tricarboxlic acid 

Relevant academic research and scientific papers

Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships

A series of novel 7β-[2-(2-aminothiazole-4-yl)-2-(Z)-(alkoxyimino)acetamido]-cephalosporins having pyridinium-linked acyl cyanamide at the C-3 position were prepared and their antibacterial activities and pharmacokinetics profiles were evaluated. Most of the compounds exhibited potent antibacterial activities against penicillin-resistant Streptococcus pneumoniae (PRSP) and β-lactamase non-producing penicillin-resistant Haemophilus influenzae (BLNAR). Introduction of a propenyl group between the cephalospoin core and the side chains at the C-3 position improved the pharmacokinetics profile. Among these compounds, 7β-[2-(2-aminothiazole-4-yl)-2-(Z)- (alkoxyimino)acetamido]-3-(pyridin-1-ium-1-yl)prop-1-en-1-yl)cephalosporins (32j) showed well-balanced antibacterial activity against S.?pneumoniae and H.?influenzae which included resistant strains and also other Gram-positive or Gram-negative pathogens. Furthermore, 32j showed a long half-life comparable to that of Ceftriaxone in mice and monkeys.

ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE

A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE

A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.